Skip to content

Percutaneous High Frequency Alternating Current Stimulation in Healthy Volunteers

Percutaneous High Frequency Alternating Current Stimulation: Effects on Somatosensory and Motor Threshold in Healthy Volunteers

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04346719
Enrollment
60
Registered
2020-04-15
Start date
2020-06-01
Completion date
2020-11-17
Last updated
2020-11-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Electrical Stimulation, Neuromodulation

Keywords

high-frequency alternating current, nerve block, somatosensory threshold, motor threshold, percutaneous electrical stimulation

Brief summary

High-frequency alternating currents of greater than 1 kHz applied on peripheral nerves has been used in animal studies to produce a motor nerve block. It has been evidenced that frequencies higher than 5 kHz are necessary to produce a complete peripheral nerve block in primates, whose nerve thickness is more similar to humans.

Detailed description

Our previous studies with transcutaneous HFAC, suggest high-frequency stimulation (10 and 20 kHz) have an inhibitory effect over muscle strength and somatosensory threshold. However, in these studies the intensity needed to reach block threshold is very high. The purpose of the present work is to reduce the amount of current intensity needed using a percutaneous approach by apply two acupuncture needles near the nerve as electrodes.

Interventions

DEVICE10 kHz stimulation (Myomed 932, Enraf-Nonius)

A charge-balanced, symmetric, biphasic sinusoidal current without modulation will be delivered at a frequency of 10 kHz. The stimulation intensity will be defined as that sufficient to produce a strong but comfortable sensation, just below motor threshold, over the median nerve through the electrotherapy device Myomed 932. (Enraf-Nonius, Delft,Netherlands)

DEVICE20 kHz stimulation (Myomed 932, Enraf-Nonius)

A charge-balanced, symmetric, biphasic sinusoidal current without modulation will be delivered at a frequency of 20 kHz. The stimulation intensity will be defined as that sufficient to produce a strong but comfortable sensation, just below motor threshold, over the median nerve through the electrotherapy device Myomed 932. (Enraf-Nonius, Delft,Netherlands)

Sham stimulation will be delivered at a frequency of 10 kHz only during the first 30 seconds.

Sponsors

University of Castilla-La Mancha
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to 60 Years
Healthy volunteers
Yes

Inclusion criteria

* Healthy volunteers * Ability to perform all clinical tests and understand the study process, as well as obtaining informed consent. * Tolerance to the application of electrotherapy. * That they have not diagnosed any pathology. * They do not present a contraindication to puncture and / or the application of electric currents.

Exclusion criteria

* Neuromuscular disease. * Epilepsy. * Trauma, surgery or pain affecting the upper limb * Osteosynthesis material in the upper limb. * Diabetes. * Cancer. * Cardiovascular disease. * Pacemaker or other implanted electrical device. * Take any drug (NSAIDs, corticosteroids, antidepressants, analgesics, antiepileptics, ...) during the study and in the previous 7 days. * Presence of tattoos or other external agent introduced into the treatment or assessment area. * Pregnancy

Design outcomes

Primary

MeasureTime frameDescription
Muscle strengthBaseline at 0 minutesMuscle strength will be measured with a dynamometer and will be expressed in Kgs.
Antidromic median sensory nerve action potentialBaseline at 0 minutesThe recording electrodes were placed on the second finger and the stimulus will be applied on the median nerve (above the elbow joint). The stimulus will consist of a train of 10 pulses (100 μs width), applied at supramaximal stimulation, presented at 1 Hz (DS7A, Digitimer Ltd). Negative peak latency (NPL), positive peak latency (PPL), and peak-to-peak amplitude (PPA) will be registered with a specific software (Signal software, CED).
Tactile ThresholdBaseline at 0 minutesThe tactile threshold will be measured with Von Frey filaments and will be expressed in millinewton
Oscillation Frequency of tissue assessed by MyotonProBaseline at 0 minutesThis outcome measure is obtained by a device named MyotonPro. The frequency of the damped oscillations characterizes the muscle tone. The muscle will be assessed is opponens pollicis muscle
Stiffness of tissue assessed by MyotonProBaseline at 0 minutesThis outcome measure is obtained by a device named MyotonPro. Stiffness reflects the resistance of the muscle to the force deforming the muscle. The muscle will be assessed is opponens pollicis muscle
Decrement (elasticity) of tissue assessed by MyotonProBaseline at 0 minutesThis outcome measure is obtained by a device named MyotonPro. The logarithmic decrement of the damping oscillations characterizes muscle elasticity which is the ability of the muscle to restore its initial shape after contraction. The muscle will be assessed is opponens pollicis muscle
Pressure Pain ThresholdBaseline at 0 minutesThe PPT will be measured with an algometer and will be expressed in Newtons

Secondary

MeasureTime frameDescription
Baseline flux temperatureBaseline at 0 minutes, at 15 minutes, immediately after treatment at 20 minutes, and immediately after treatment at 30 minutesFlux will be measured using a termodoppler
Numerical Discomfort Rate ScoreAfter the intervention at 35 minutesthe possible discomfort caused by the interventions will be assess by a numerical rate score. The NRS consists of a scale from 0 (no discomfort) to 10 (worst possible discomfort)
Numerical Pain Rate ScoreAfter the intervention at 35 minutesThe NRS consists of a scale from 0 (no pain) to 10 (worst possible pain)
Number of participants with intervention-related adverse effectsAfter the intervention at 35 minutesthe possible adverse effects caused by the interventions will be assess by a questionnaire
Blinding successAfter the intervention at 35 minutesBlinding of subjects and researchers will be assessed using the James Index
Baseline nerve temperatureBaseline at 0 minutes, at 15 minutes, immediately after treatment at 20 minutes, and immediately after treatment at 30 minutesNerve temperature will be measured using a termodoppler (Celsius degrees)

Countries

Spain

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026